ClinicalTrials.gg
CompletedNCT01103830Updated Jun 17, 2011

Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers

A Phase 1 interventional study of Eurartesim™ and Riamet® in Malaria, Falciparum, sponsored by sigma-tau i.f.r. S.p.A.. Completed at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-17.

Sponsored by sigma-tau i.f.r. S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
287
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing artenimol in Malaria, Falciparum — 1 open to participants now, 3 under way, 1 of them phase 3. artenimol · Malaria, Falciparum.

Enrollment
18th of 23
287 · median 663
Started
2010
with 3 others
Phase 1
3 of 23
none open now
Registered
2nd of 23
by date
Lead sponsor
3 of 23
sigma-tau i.f.r. S.p.A.

Among the 23 studies testing artenimol in Malaria, Falciparum, this one is the 18th largest by enrollment, is one of 4 that started in 2010, is one of 3 in phase 1, and was the 2nd registered.

Malaria, Falciparum

456 studies on the registry are indexed under Malaria, Falciparum; 38 are open to participants now.

Browse Malaria, Falciparum studies →

Open to participants now

1 of the 23 studies testing artenimol in Malaria, Falciparum is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About artenimol

artenimol: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Malaria, Falciparum studies recruiting now, 6 (27%) set no upper age limit and 15 (68%) stop at 75 or younger; 14 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing artenimol in Malaria, Falciparum, or all of them as a file.
02

Study summary

The aim of such a study is to evaluate the impact of a therapeutic dose of Eurartesim™ compared to Riamet®, after multiple dose administration for 3 days in healthy male and female subjects on electrocardiographic parameters.

Read the detailed description

The fight against malaria, which the WHO reactivated in 1999 with its Roll Back Malaria programme, emphasizes early curative treatment of malaria, particularly in children, in order to decrease mortality and morbidity. Recent estimates confirm a disturbing persistence of endemic malaria with around 515 million cases and 1.0 million deaths per year.The available range of standard antimalarial drugs is narrow. There are only four classes of compounds, probably with different mechanisms of action: 4-aminoquinolines, amino-alcohols, artemisinin derivatives (isolated from a plant, Artemisia annua), and antifolates and drugs related to them.

From a public health perspective, drug resistance is a critical factor that undermines malaria control.Plasmodium falciparum and resistance to chloroquine and sulfadoxine/pyrimethamine is widespread. At present, natural quinine is still effective against P. falciparum everywhere in the world except partially in South-east Asia and South America, where decreased susceptibility is reported. Only the artemisinin derivatives, used for 15 years in Asia and, more recently in Africa, have not generated clinical resistance. Overcoming or reducing resistance requires the adoption of several strategies; central to these is the use of effective chemotherapy for those who need it. In addition, to new molecules, we need to develop and implement strategies to protect drugs against resistance. Resistance to single-drug therapies will inevitably occur. Drug combinations, which have been standard practice for viral and bacterial diseases, are now being adopted for malaria as well. The artemisinin derivatives in combination with standard antimalarials are now being promoted as the best therapeutic option for treating drug-resistant malaria and retarding the development of resistance.

The aim of the present study is to investigate the effect of this new Artemisinin Combination Therapy (ACT) formulation on electrocardiographic parameters. In the literature no relevant QT prolongation associated with Piperaquine treatment has been reported in not-company sponsored trials but no specific TQT trials have been published. On the contrary it has been reported that quinine, quinidine and halofantrine induced a QT prolongation (from slight to severe).

03

Conditions studied

  • Malaria, Falciparum

Browse trials for

Keywords

  • P. falciparum Malaria, Eurartesim, ACT
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Caucasian subject ≥ 18 and ≤ 50 years;
  • Good general health (by medical history and physical examination);
  • For male and female subjects of use a double method;
  • For female subjects of childbearing potential only: negative plasma pregnancy test at Screening and at admission in the clinical unit;
  • (BMI) ≥18 and ≤ 27 kg/m2;
  • No abnormalities in blood pressure and heart rate;
  • No clinically relevant abnormalities in 12-lead results;
  • No clinically relevant abnormalities in results of laboratory tests;
  • Registered with the French Social Security in agreement with the French law on biomedical experimentation.

Exclusion criteria

Exclusion Criteria:

  • A predictable poor compliance or inability to communicate well with the Investigator;
  • Unsuitable veins for repeated venipuncture.
  • Evidence of cardiovascular, renal, hepatic, hematological, gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or psychiatric diseases as judged by the Investigator;
  • A history of additional risk factors for Torsades des Pointes (e.g., heart failure, hypokalemia, family history of Long Syndrome);
  • The use of concomitant medications that prolong the QT/QTc interval;
  • Any condition requiring regular concomitant medication, including herbal products and over-the-counter (OTC) medication or predicted need of any concomitant medication during the study;
  • Evidence of any clinically significant acute or chronic disease, including known or suspected , virus (HBV) and infection;
  • History of relevant clinical allergic reactions of any origin;
  • Known to any of the test materials or related compounds;
  • Intake of any medication (except paracetamol, hormonal and hormone replacement therapy for women), including OTC medications and herbal products that could affect the outcome of the study, within 2 weeks prior to the first drug administration or less than 5 times the t1/2 of that drug, whichever is the longer;
  • Drug abuse;
  • Current use of nicotine containing products and the inability to stop using nicotine containing products during confinement in the clinical centre.
  • Use of caffeine containing beverages exceeding 500 mg caffeine/day and the inability to refrain from the use of caffeine containing beverages during confinement in the clinical centre;
  • Intake of any food or any beverage containing grapefruit or grapefruit juice, orange or pomelo juice within 48 h prior to the first dosing and the inability to stop such intake during the study;
  • Blood donation or loss of significant amount of blood within three months prior to the first dosing;
  • Positive drug screen;
  • Positive serology to HIV (HIV1 and HIV2) and/or HCV antibodies, and/or hepatitis B surface antigen (HBsAG);
  • Any other condition that in the opinion of the Investigator would interfere with the evaluation of the results or constitute a health risk for the subject;
  • Participation in a drug study within 3 months prior to the first dosing.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
287 participants (actual)

Study arms

  • Experimental
    Group 1

    3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3. Administration of Eurartesim will be in fed condition following a high-fat/low-Kcal meal.

    Drug: Eurartesim™

  • Active comparator
    Group 2

    4 tablets of Riamet® on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3. Administration of Riamet® will be in fed condition following a high-fat/low-Kcal meal.

    Drug: Riamet®

  • Other
    Group 3

    3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3. Administration will be in the morning, in fed condition, following a high-fat/low-Kcal meal 1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning.

    Other: Placebo and finally Moxifloxacin

  • Experimental
    Group 4

    3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3. Administration of Eurartesim will be in fed condition following a high-fat/high-Kcal meal.

    Drug: Eurartesim™

  • Experimental
    Group 5

    3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3. Administration of Eurartesim will be in fasting condition.

    Drug: Eurartesim™

  • Other
    Group 6

    3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3. Administration will be in the morning, in fasting condition. 1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning.

    Other: Placebo and finally Moxifloxacin

Interventions

  • DrugEurartesim™

    Drug pages: Artenimol · Piperaquine

    3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3

    Also known as: Dihydroartemisinin and Piperaquine combination therapy

  • DrugRiamet®

    4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.

    Also known as: artemether and lumefantrine combination therapy

  • OtherPlacebo and finally Moxifloxacin

    3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3. 1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning.

    Also known as: moxifloxacin

  • DrugEurartesim™

    Drug pages: Artenimol · Piperaquine

    3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.

    Also known as: Dihydroartemisinin and Piperaquine combination therapy

  • DrugEurartesim™

    Drug pages: Artenimol · Piperaquine

    3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.

    Also known as: Dihydroartemisinin and Piperaquine combination therapy

  • OtherPlacebo and finally Moxifloxacin

    3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3. 1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning.

    Also known as: moxifloxacin

06

What researchers measure

Primary outcomes

  1. QTcF interval (Fridericia's correction QT interval)

    Group 1,4 and 5 (Day -1: pre-dose, each hour till 13h post-dose. Day 1: pre-dose, 1, 2, 3, 4, 5, and 6 h post-dose. Day 3: pre-dose, each hour till 13h post-dose and then 24h). Group 2 (Day -2: pre-dose, each hour till 13h post-dose and then 24h. Day 3: pre-dose, each hour till 13h post-dose and then 24h). Group 3 and 6 (Day -1: pre-dose, each hour till 13h post-dose. Day 1: pre-dose, 1, 2, 3, 4, 6, 8, 12 and 24h post-dose. Day 3: pre-dose, pre-dose, each hour till 13h post-dose. Day 4: pre-dose, 1, 2, 3, 4, 6, 8, 12 and 24h post-dose).

    Time frame: before study drugs administration, during the 24 hrs post first and third dose and during follow-up

Secondary outcomes

  1. Effect of Eurartesim™ administered in different food conditions, on ECG parameters

    To evaluate the impact of a therapeutic dose of Eurartesim™ under different food intake conditions on the cardiac activity, as expressed by ECG parameters.

    Time frame: before study drugs administration, during the 24 hrs post first and last dose and during follow-up

  2. Effect of food on bioavailability of Eurartesim™

    To evaluate the impact of high-fat/high-Kcal or high-fat/low-Kcal meals on the overall relative bioavailability of Eurartesim™ in respect to no food.

    Time frame: during the 24 hrs post first and last dose

  3. To evaluate differences in PK and ECG profiles according to posology scheme

    To compare, within the Eurartesim™ groups, the PK profiles and the QT intervals of subjects with a body weight below or equal and above 75kg

    Time frame: during the 24 hrs post first and last dose

  4. relationship within the Pk parameters of active substances and ECG parameters

    To evaluate the relationship between the PK parameters of Dihydroartemisinin and Piperaquine and the ECG parameters

    Time frame: during the 24 hrs post first and last dose

  5. to asses general safety and tolerability of Eurartesim™

    To assess the safety and tolerability of Eurartesim™ under different food intake conditions in healthy subjects

    Time frame: during the treatment and follow-up period

07

Study locations

1 site
  • SGS aster s.a.s
    Paris, 75015, France
08

References and documents

Publications

  • Funck-Brentano C, Bacchieri A, Valentini G, Pace S, Tommasini S, Voiriot P, Ubben D, Duparc S, Evene E, Felices M, Corsi M. Effects of Dihydroartemisinin-Piperaquine Phosphate and Artemether-Lumefantrine on QTc Interval Prolongation. Sci Rep. 2019 Jan 28;9(1):777. doi: 10.1038/s41598-018-37112-6. PubMed 30692558 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Aug 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2010
First posted
Apr 15, 2010
Start
Feb 2010
Primary completionActual
Aug 2010
CompletionActual
Dec 2010
Last update
Jun 17, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01103830
Lead sponsor
sigma-tau i.f.r. S.p.A.
Collaborators
Medicines for Malaria Venture
First posted
Apr 15, 2010
Start date
Feb 2010
Primary completion
Aug 2010
Completion
Dec 2010
Last update
Jun 17, 2011

Study contacts

Lionel Hovsepian, MD
principal investigator · SGS Aster S.A.S.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Artenimol · Piperaquine

Start the discussion